Vitamin-D Status and Sex-Hormone Binding Globulin - Determinants of Bone Turnover and Bone-Mineral Density in Elderly Women by Ooms, M.E. et al.
JOURNAL OF BONE AND MINERAL RESEARCH
Volume 10, Number 8, 1995
Blackwell Science, Inc.
Vitamin D Status and Sex Hormone Binding Globulin:
Determinants of Bone Turnover and Bone Mineral
Density in Elderly Women
MARCEL E. 00MS, 1 PAUL LIPS, 12 JAN C. ROOS, 3
 WIM J.F. VAN DER VIJGH,4
CORRIE POPP-SNIJDERS, 5 P. DICK BEZEMER, 6 LEX M. BOUTER1'6
ABSTRACT
To examine the relation of the vitamin D status and the remaining estrogen activity with bone turnover and bone
mineral density (BMD) in elderly women, BMD was measured at both hips using dual-energy X-ray absorp-
tiometry and at the distal radius using single photon absorptiometry, in 330 healthy women aged 70 and over.
Vitamin D metabolites, sex hormone binding globulin (SHBG), PTH(1-84), osteocalcin, alkaline phosphatase, and
hydroxyproline and calcium excretion in 2 h fasting urine were measured. Multiple linear regression was used to
adjust for potential confounders. In 65% of the women, serum 25(OH)D was below 30 nmo1/1. Only values below
a threshold for 25(OH)D were negatively related to serum PTH(1-84) (p = 0.02, threshold at 25 nmo1/1) and to
osteocalcin levels (p = 0.04, threshold at 30 nmo1/1). BMD of the femoral neck and trochanter was positively
related to serum 25(OH)D (left neck p = 0.001) with thresholds at 30 nmo1/1 whereas the distal radius was not (p
= 0.32). Serum PTH was negatively related to BMD at all measurement sites (all p < 0.001). Serum SHBG, an
inverse measure of estrogen activity, was positively related to osteocalcin levels (p = 0.004) and the urinary
hydroxyproline/creatinine ratio (p = 0.002) and negatively related to the BMD of the trochanter (left trochanter
p = 0.02) and the distal radius (p = 0.001). We conclude that in elderly women, serum 25(OH)D levels below 30
nmo1/1 are associated with secondary hyperparathyroidism and increased bone turnover. SHBG is positively
related to bone turnover. Vitamin D deficiency especially influences BMD of the femoral neck, a cortical area.
SHBG mainly influences BMD at the trochanteric region and distal radius, predominantly trabecular areas, which
may reflect the effects of remaining estrogen activity. (J Bone Miner Res 1995;10:1177-1184)
INTRODUCTION
0 STEOPOROSIS IS A DISEASE CHARACTERIZED BY DECREASEDBONE MASS and structural deterioration resulting in a
higher risk of fractures. Hip fractures are an especially
important cause of morbidity and mortality in the elderly.")
The decreasing bone mass (2)
 and the increasing risk of
fal1s(3) account for the sharp rise in the hip fracture inci-
dence with age. Women as well as men lose bone with age,
but in women the onset of menopause aggravates bone
loss, (4)
 while later in life other factors, such as vitamin D
deficiency, may play a ro1e.(5)
Vitamin D deficiency is common in the elderly. (5) Pa-
tients with a hip fracture usually have a poorer vitamin D
status than age-matched controls." The levels of 25-
hydroxyvitamin D (25(OH)D) decline with age, due to
lesser exposure to sunshine and decreased production in
the aging skin. (6 '7)
 Regular nutrition does not compensate
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for this."'" ) Severe, long-standing vitamin D deficiency
leads to osteomalacia, but this is uncommon." ) Nevertheless,
vitamin D deficiency may play a role in the pathogenesis of
osteoporosis in the elderly. It leads to decreased production of
the active metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D).
It is the main stimulator of the calcium absorption from the
gut and indirectly as well as directly inhibits parathyroid
hormone (PTH) production. (5•9) The increased secretion of
PTH in the case of vitamin D deficiency increases bone
turnover and bone loss and will lead to decreased mineral-
ization of newly formed bone. /5) Seasonal variation of se-
rum concentrations of 25(OH)D and 1,25(OH),D and an
inverse variation of serum PTH levels have been found in
elderly groups. (8,10,11) Vitamin D supplementation in the
case of vitamin D deficiency increases 1,25(OH)2D levels
and suppresses PTH secretion in elderly patients." 2) The
boundary between a normal and deficient vitamin D status
is still a matter of discussion."3)
In the first years after the onset of menopause, women
lose bone at a much faster rate than premenopausal
women. The rate of bone loss then gradually decreases,(4)
but this may partly depend on the remaining endogenous
estrogen production from adrenal androstenedione in adi-
pose tissue. (14,15) Sex hormone binding globulin (SHBG)
binds the circulating sex hormones and is the major inverse
determinant of the level of free (active) hormone." 6) In-
deed, SHBG is a better predictor of BMD and bone loss
than the total endogenous estrogen levels, which suggests
that it is a suitable measure for the remaining oestrogen
activity." 7-19) Higher levels of SHBG have been found in
patients with vertebral crush fractures when compared with
controls" 7) as well as in patients with hip fracture. (20) Re-
cently we found in women over 70 years of age that the
relation of the number of years since menopause with BMD
of the hip was stronger than its relation with chronological
age. (21) These data suggest a relation between the remain-
ing estrogen activity and osteoporosis even long after meno-
pause. However, no studies have been done on the relation
of SHBG to bone turnover and BMD in very old people.
In the present paper, we present data on the influence of
the remaining oestrogen activity and the vitamin D status
on PTH secretion, parameters of bone turnover, and BMD
in a group of healthy elderly women.
MATERIALS AND METHODS
Baseline measurements were taken in women aged 70
and over participating in a clinical trial on the effect of
vitamin D supplementation on the incidence of hip frac-
tures. Women who were residents of homes or apartments
for the elderly were asked to participate in an additional
study involving BMD measurements. The protocol was ap-
proved by the Free University Hospital Ethical Committee.
All participants gave informed consent. In order to be able
to visit the hospital for these measurements, the women had
to be reasonably mobile. Exclusion criteria for entry in the
trial were: hip fracture in the past, total hip prosthesis, and
recent history of urolithiasis, hypercalcaemia, or sarcoid-
osis. Women taking vitamin D supplements at baseline or
suffering from primary hyperparathyroidism were excluded.
The date of the measurement was classified by season.
Exposure to sunshine was determined by an outdoor fre-
quency score (0: <1 time/week outdoors, 1: 1-2 times/week
outdoors, 2: 3 times/week outdoors) and a sunshine pref-
erence score (0: prefers shade, 1: prefers some sunshine, 2:
prefers sunshine). Height and body weight were measured
while the participants wore indoor clothes and no shoes.
BMD measurements
BMD was measured by single photon absorptiometry
(SPA; Norland OsteoAnalyser) at the distal radius of the
dominant forearm. The long-term coefficient of variation in
a group of 27 volunteers and osteoporotic patients was
3.1% (local unpublished results). The BMD of both hips
was measured using dual-energy X-ray absorptiometry (DXA;
Norland XR-26, Norland Corp., Fort Atkinson, WI) at the
femoral neck and the trochanter. All DXA scans were
reanalyzed by one observer to increase precision, with the
most recent Norland software version 2.3.0 which enables
rotation of the regions of interest in one plane. The long-
term coefficient of variation in a group of 50 volunteers and
osteoporotic patients was 2.1% for the femoral neck and
2.4% for the femoral trochanter (local unpublished results
with earlier software version).
Biochemical measurements
Blood samples and 2 h morning urine samples (22) were
obtained in fasting subjects. Osteocalcin was measured us-
ing a radioimmunoassay kit from the Incstar Corporation
(Stillwater, MN). Serum intact PTH (PTH(1-84)) was mea-
sured in plasma using a two-step immunochemical method
involving amino-terminal immunoextraction followed by a
midregion immunoassay. The interassay coefficient of vari-
ation (CV) of this method is 10.2%. (23) Measurements of
the vitamin D metabolites were performed with competitive
protein binding assays after isolation by gradient HPLC.
The intra- and interassay CVs are 5% and 6%, respectively,
for 25(OH)D and 6% and 15% for 1,25(OH) 2D. (24) Mea-
surement of SHBG was performed using an IRMA kit from
Farmos Diagnostica with an interassay CV of 5.3% (Ou-
lunsalo, Finland). Hydroxyproline was measured by HPLC
with an interassay CV below 3.2% (25) and expressed as a
hydroxyproline/creatinine ratio (Hp/Cr). Serum alkaline
phosphatase, calcium, phosphate, albumin, and creatinine
were measured using standard laboratory methods. Serum
calcium was corrected for serum albumin using the follow-
ing equation: corrected calcium = serum calcium + [40 -
albumin (g/1)] x 0.02 mmol/l.
Statistical analysis
Statistical analysis was performed using SPSS-PC. All
relationships were analyzed with multiple linear regression
analysis (MLR) with correction made for possible con-
founding. Regression equations were checked for linearity
of the relation, normal distribution, and stability of vari-
ance. Nominal variables (e.g., season) and ordinal variables
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TABLE 1. MEAN (SD) FOR AGE, YEARS SINCE MENOPAUSE,
ANTHROPOMETRIC DATA, AND BMD (g/cm2) IN 330
PARTICIPATING WOMEN
Age (years) 80.3 (5.6)
Years since menopause 32.5 (7.1)
Body weight (kg) 71.2 (11.4)
BMI* (kg/cm2) 28.3 (4.0)
BMW- left femoral neck (g/cm2) 0.687 (0.106)
BMD right femoral neck 0.680 (0.105)
BMD left trochanter 0.604 (0.111)
BMD right trochanter 0.595 (0.109)
BMD distal radius 0.318 (0.081)
* Body mass index.
Bone mineral density.
(e.g., outdoor frequency and sunshine preference scores)
were entered in the regression model as separate indicator
variables for each category. When necessary, log transfor-
mations of dependent and independent variables were per-
formed. The relationship of 25(OH)D and SHBG with
PTH(1— 84), parameters of bone turnover, and BMD were
examined in a single regression model for each dependent
variable. Since the relationship of 25(OH)D with most de-
pendent variables was obviously nonlinear, various trans-
formations were performed. These included logarithmic
and inverse transformations as well as thresholds. In case of
threshold transformations, serum 25(OH)D levels above
certain values, ranging from 15-45 nmo1/1 with steps of 5
nmol/l, were recoded to the value of the threshold. This
transformation implicates that no relation is assumed above
the threshold. After each transformation, the fit of the
regression model was tested, and the transformation with
the best fit was reported. A high fit of a threshold transfor-
mation indicates a distinct boundary between a vitamin
D— deficient and —replete state. Interaction of the effects of
25(OH)D and SHBG was tested by entering the product
term of the transformations of SHBG and 25(OH)D with
the best fit in the regression model. All reported p values
are two-sided.
RESULTS
Of the total of 348 women who underwent the BMD
measurements, one suffered from primary hyperparathy-
roidism and 17 were taking vitamin D—containing tablets
and were therefore excluded from the analysis. Mean values
for age, years since menopause (YSM), body weight, BMI,
and BMD of the remaining 330 women are shown in Ta-
ble 1. Table 2 shows the mean, standard deviation, median,
5th, and 95th percentiles for the biochemical parameters in
blood and 2 h fasting urine. The percentiles of serum-
corrected calcium and phosphate were within the reference
values provided by the laboratory.
Determinants of 25(OH)D and SHBG levels
In 65% of all subjects, the serum 25(OH)D level was
below 30 nmo1/1, and in 34% it was below 20 nmo1/1. In
winter 83% and in summer 50% of the 25(OH)D levels
were below 30 nmol/l. The median levels of serum
25(OH)D were significantly higher for inhabitants of apart-
ments for the elderly than residents of homes for the elderly
(29.0 and 22.0 nmo1/1, respectively; p < 0.001). The vitamin
D status was related to age (p < 0.0001), outdoor fre-
quency score (p = 0.004), sunshine preference score (p <
0.0001), and season (p < 0.0001). The multiple linear
regression (MLR) model that included these four indepen-
dent variables accounted for 26% of the variance of serum
25(OH)D. Vitamin D values at age 90 were 15.3% lower
than at age 70, corrected for season, the sunshine prefer-
ence, and outdoor frequency scores. Table 3 shows the
median 25(OH)D levels by sunshine preference and out-
door frequency scores in the summer. The levels were
highest in the summer and lowest in the winter. In stepwise
MLR, serum SHBG was best determined by age and body
weight, while adding the number of years since menopause,
age at menopause, or BMI to the model did not result in a
significant improvement. According to this model, serum
SHBG was significantly higher in older subjects (+1.41
nmo1/1/year; p = 0.0001), and lower in heavier subjects
(-0.74 nmol/l/kg; p = 0.0001).
Relation of 25(OH)D and SHBG with 1,25(OH)2D,
PTH(1-84), and parameters of bone turnover
Serum 1,25(OH)2D, corrected for age and serum creati-
nine, showed a significant variation over the seasons (p <
0.0001), parallel to the variation in serum 25(OH)D levels,
as shown in Fig. 1. The serum 1,25(OH) 2D levels were
related to 25(OH)D levels over the whole range (p <
0.0001), independent of age and serum creatinine. How-
ever, 1,25(OH) 2D increased linearly with the logarithm of
25(OH)D, implicating a stronger relation at the lower end
of the 25(OH)D range.
To determine the relation of serum 25(OH)D and SHBG
with bone turnover, a single MLR model was made for each
bone turnover parameter in which we corrected for age, age
at menopause, and serum creatinine. The relation of
25(OH)D with the logarithm of PTH(1— 84) was best de-
scribed by a linear model with a threshold for 25(OH)D at
25 nmo1/1, which represents a negative relation below and
no relation above the threshold. Below this threshold, PTH
increased 14.1% for every 10 nmo1/1 of lower serum
25(OH)D (p = 0.02). Likewise serum osteocalcin was 0.3
p,g/I higher for every 10 nmo1/1 of lower serum 25(OH)D
(p = 0.04) below a threshold at 30 nmo1/1. No significant
relation of serum 25(OH)D was found with alkaline phos-
phatase and the fasting urinary Ca/Cr and Hp/Cr ratio (all
p > 0.15). Higher serum SHBG levels were significantly
associated with higher serum osteocalcin (+0.6 p.g/1 for a
doubling of SHBG, p = 0.004) and urinary Hp/Cr ratios
(+ 15.7% for a doubling of SHBG, p = 0.002), but not to the
levels of serum PTH(1— 84), alkaline phosphatase, and the
fasting urinary Ca/Cr ratio (all p > 0.56).
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TABLE 2. MEAN (SD), MEDIAN, 5TH, AND 95TH PERCENTILES FOR BIOCHEMICAL PARAMETERS IN
BLOOD AND 2 H FASTING URINE
Parameter
Mean
(SD) Median
5th and 95th
percentile
Reference
values*
25(OH)D (nmol/1) 28.1 (13.0) 25.0 13.0-50.0 30-100
1,25(OH) 2D (pmo1/1) 114 (34) 111 63-177 60-160
SHBGt (nmo1/1) 61.8 (29.9) 56.0 23.0-120.0 20-140
PTH(1-84) (pmo1/1) 3.9 (2.4) 3.4 1.7-8.7 <0.5-4.0
Ca/Cr..ine* (mmol/mmol) 0.33 (0.22) 0.28 0.07-0.82 <0.45
Hp/Crurme* (panol/mmol) 22 (9) 21 12-38 <25
Osteocalcin (i.tg/l) 3.9 (1.8) 3.5 1.7-7.0 1.8-6.6
Alkaline phosphatase (U/1) 68 (20) 65 42-107 <90
Calcium (corrected) (mmo1/1) 2.38 (0.10) 2.37 2.21-2.56 2.20-2.60
Phosphate (mmo1/1) 1.05 (0.13) 1.05 0.84-1.26 0.70-1.40
Creatininc (mmol/1) 86.9 (19.0) 83.0 65-120 60-110
Albumin (WI) 36.5 (2.6) 36.0 32-41 35-50
* Local, in healthy adults.
*Sex hormone binding globulin.
*Calcium creatinine ratio.
Hydroxyproline creatinine ratio.
TABLE 3. MEDIAN SERUM 25(OH)D IN nmo1/1* AND NUMBER OF PARTICIPANTS t (n), BY
SUNSHINE PREFERENCE SCORE AND OUTDOOR FREQUENCY SCORE IN THE SUMMER AND THE
DIFFERENCES FOR THE OTHER SEASONS
Outdoor frequency
Estimated for summer 	 <1 time!	 1-2 times!	 3 times/
sunshine preference	 week	 week	 week	 Difference in
Avoids sunshine 19.7 22.5 25.3
(n = 13) (n = 7) (n = 58) winter - 26.0%
Prefers some sunshine 22.1 25.4 28.5
(n = 14) (n = 14) (n = 97) spring -12.2%
Prefers sunshine 26.3 30.1 33.9
(n = 2) (n = 8) (n = 117) autumn -5.5%
* Estimated by multiple regression analysis corrected for age: values for the other seasons can be
obtained by subtracting the appropriate percentage from median 25(OH)D levels.
n indicates the total number of participants in a particular category.
Relation of serum PTH, 25(OH)D, and SHBG with
BMD
Serum PTH was negatively related to BMD at all mea-
surement sites (all p < 0.001). The correlation coefficient
ranged from -0.19 for the distal radius to -0.27 for the left
femoral neck. Figure 2 shows the relationship of 25(OH)D
with BMD at the left femoral neck, adjusted in an MLR
model for mean age, age at menopause, body weight, and
SHBG. For the BMD of the hip, the best fit was obtained
with a threshold at 30, similar to the relation of serum
25(OH)D to serum PTH(1-84) and osteocalcin. In Table 4,
the differences in BMD, for every 10 nmo1/1 of higher
25(OH)D up to the threshold, are shown. There was a
significant relation of 25(OH)D with BMD at the left and
right femoral neck and the right trochanter, a borderline
significant relation at the left trochanter, and no significant
relation at the distal radius. As shown in Table 4, a higher
SHBG level was significantly associated with lower BMD at
all measurement sites but the left femoral neck. The stron-
gest relation of SHBG with BMD, however, was found for
the distal radius (Fig. 3).
Interaction of serum 25(OH)D and SHBG
Interaction was tested by entering the product-term
25(OH)D * SHBG in the regression models. Low serum
25(OH)D in combination with high serum SHBG was as-
sociated with higher levels of PTH(1-84) than was ac-
counted for by its independent relation with 25(OH)D and
SHBG, as shown in Fig. 4 (p = 0.04). No significant inter-
action of serum 25(OH)D and SHBG was observed for
1,25(OH) 2D, parameters of bone turnover, nor BMD at all
measurement sites (data not shown).
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FIG. 1. Seasonal variation of serum 25(OH)D, nmo1/1
(p < 0.0001), adjusted for age, sunshine preference score
and outdoor frequency score, and serum 1,25(OH)2D,
pmo1/1 (p < 0.0001) adjusted for age and serum creatinine.
BMD left femoral neck, g/cm 2 (log-scale)
10	 20	 30	 40	 50	 60	 70	 80
25(OH) vitamin D, nmol/L
FIG. 2. Relation of BMD of the left femoral neck with
serum 25(OH)D (p = 0.001), adjusted for serum SHBG,
age, age at menopause, and body weight.
DISCUSSION
We studied the influence of the vitamin D status and the
remaining estrogen activity on bone metabolism and BMD
in a group of elderly women. Although the results are based
on cross-sectional data, the validity of the results was en-
hanced by correction for important potential confounders
with multiple regression. The average vitamin D status of
the subjects was poor, similar to what has been found in
other studies in the elderly,"s which is caused by the
decreasing capacity of the skin for vitamin D synthesis with
aging/7) as well as lesser exposure to sunshine. In our study,
this is illustrated by the separate relations of the serum
25(OH)D concentrations with age, outdoor frequency, and
sunshine preference scores. It has been suggested that vi-
tamin D deficiency may contribute to hip fracture risk in the
elderly by decreasing calcium absorption, with subsequent
mineralization defects and secondary hyperparathyroidism,
leading to increased bone turnover and cortical bone
loss. (5•26) Our study supports this hypothesis. The parallel
variation over the seasons and the positive relation of
1,25(OH)2D with 25(OH)D indicate that the production of
1,25(OH) 2D is substrate-dependent in the case of vitamin
D deficiency. This has been observed in other studies as
well. 10,12) Low serum 25(OH)D concentrations were asso-
ciated with higher PTH and osteocalcin concentrations and
lower BMD of the hip. Higher serum PTH levels were
associated with lower BMD at all measurement sites, which
suggests that the lower BMD in the case of vitamin D
deficiency may be due to secondary hyperparathyroidism.
Similar relations have been found in other groups of elderly
people with comparable 25(OH)D concentrations. (11,12,27,28)
In a recent cross-sectional study in the U.K., a positive
relation between serum 25(OH)D concentrations and
BMD of the lumbar spine, the femoral neck, and trochanter
was observed in a group of middle-aged women, but these
women had low 25(OH)D concentrations as well. (29) Be-
cause these relations are improbable in a vitamin D—replete
status, and inspection of the data suggested a clearly non-
linear relation, we examined the possibility of a threshold
phenomenon. It appeared that the vitamin D status was
negatively related to PTH and osteocalcin levels and posi-
tively to the BMD of the hip, but only when serum
25(OH)D was lower than approximately 30 nmo1/1. Above
this threshold no relationship was found. This suggests that
the boundary between a deficient and a replete vitamin D
status in Dutch elderly women is at 30 nmo1/1. Dawson—
Hughes et al. (30) observed in a group of North American
postmenopausal women that a vitamin D plus calcium sup-
plement (377 mg/day) decreased wintertime bone loss in
the spine and the whole body when compared with the
calcium supplement alone. The mean 25(OH)D concentra-
tions in the placebo group in that study ranged, depending
on the period, from 61-81 nmo1/1 (95% CI 56-66 and
77-86 nmo1/1, respectively). This is well above the threshold
observed in our study and seems to preclude vitamin D
deficiency. This may be explained by differences in the
25(OH)D assays. (31) Another explanation might be that in
that study the mean calcium intake from supplements and
food was approximately 700-800 mg/day. The dietary cal-
cium intake of the Dutch elderly women in our study was
much higher: 921 mg/day from dairy products alone, impli-
cating that the total mean calcium intake will be well above
1100 mg/day. (21) In populations with a lower calcium intake,
the calcium absorption from the gut will depend more on
vitamin D—mediated active absorption than on passive dif-
fusion. (32) Serum 1,25(OH) 2D is inversely related to cal-
cium intake (33) and, therefore, the threshold may be higher
when the calcium intake is low.
Our data and the fact that vitamin D supplementation
has been shown to increase serum 1,25(OH) 2D and sup-
press PTH secretion in vitamin D— deficient elderly,( 12,32)
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TABLE 4. DIFFERENCES (%) FOR BMD FOR EACH 10 nmo1/1 OF HIGHER SERUM 25(OH)D UP
TO THE THRESHOLD, AND FOR A DOUBLING OF SERUM SEX HORMONE BINDING GLOBULIN
(SHBG), CORRECTED IN REGRESSION MODELS FOR AGE, AGE AT MENOPAUSE,
AND BODY WEIGHT
25(OH)D	 SHBG
% difference/	 % difference/
BMD
	
Threshold
	
10 nmol/l	 p*
	
doubling	 P*
Left femoral neck 30 5.0 0.001 -1.4 0.43
Right femoral neck 30 3.8 0.004 -3.4 0.05
Left femoral trochanter 30 2.5 0.13 -4.8 0.02
Right femoral trochanter 30 3.2 0.05 -4.5 0.03
Dominant distal radius -1.2 0.32 -10.5 0.001
* Two-sided p values of 25(OH)D and SHBG in the multiple regression model.
BMD distal radius, g/cm 2 (log scale)	 PTH(1-84), pmol/L
7
6
5
4
3
2
1
0 	
- - -
	 high SHBG
	
 median SHBG
	  low SHBG
SHBG, nmol/L (log scale) 	 10	 20	 30	 40	 50	 60	 70	 80
	 90
FIG. 3. Relation of BMD of dominant distal radius with
serum sex hormone binding globulin (SHBG, p = 0.001),
adjusted for serum 25(OH)D, age, age at menopause, and
body weight.
suggest that vitamin D supplementation may prevent bone
loss from the hip and hip fractures in the elderly. At a serum
25(OH)D level of 10 nmo1/1 the BMD of the left femoral
neck was 9.3% lower, which is 0.6 SD below the average
BMD for an adequate vitamin D status, i.e. above 30 nmo1/1.
According to the recent data of Cummings et al., (34) this
would result in a relative risk of hip fracture of 1.8.
SHBG has been found to be a predictor of BMD and
bone loss, superior to endogenous estrogen levels in
younger groups of women. (17 ' 19) SHBG is the principal
determinant of the level of free (active) estrogen and tes-
tosterone. SHBG was considerably higher in older women
and lower in heavier women. The control of SHBG con-
centrations is very complex but probably involves estrogens
(+), testosterone (-), insulin levels (-), and the nutritional
status, especially lipids (-). With aging the androgen levels
decrease, which might account for the increase in the
SHBG levels. Obesity is often associated with higher lipid
and insulin levels, which may be an explanation for the
25(OH) vitamin D, nmol/L
FIG. 4. Relation of serum PTH(1- 84) with serum
25(OH)D, for a low, median, and high serum sex hormone
binding globulin (SHBG; 23, 56, and 120 nmo1/1, respective-
ly), adjusted for age, age at menopause, and serum creati-
nine. The error bars indicate the standard error for the
effect of SHBG on the slope of the regression lines (p =
0.04).
lower SHBG levels in the heavier subjects. (16•35) In this
study in elderly women, a higher SHBG level was associated
with higher bone turnover and lower BMD at the femoral
trochanter and the distal radius. The fact that age and body
weight are related to BMD as well as SHBG may account
for this. (21) However, even after adjusting for age and body
weight, the relation of SHBG with BMD remained. It has
been proposed that the loss of calcium from the skeleton
due to oestrogen deficiency will decrease PTH secretion.(36)
This might counteract the PTH elevating effect of the de-
creased calcium absorption caused by vitamin D deficiency.
In our study, however, higher SHBG levels were associated
with higher PTH levels in vitamin D- deficient elderly
women only, which is in contradiction with the former.
There are some data, however, that indicate that estrogen
0.5
0.4
0.3
0.2
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deficiency, i.e. high SHBG, may decrease calcium ab-
sorption directly(') or cause resistance of the gut to
1,25(OH) 2 D. (38)
 In vitamin D- deficient elderly, compensa-
tion for decreased calcium absorption by increasing
1,25(OH) 2D levels may be impaired due to substrate defi-
ciency, resulting in a further increase of PTH levels.
Although the relation of SHBG with BMD may be ex-
plained by its effect on bone loss during previous years, the
higher osteocalcin and Hp/Cr ratio in participants with high
SHBG reflect a currently increased bone turnover. Al-
though we did not measure free estrogen and androgen
levels, this suggests that even in the very old estrogen
activity plays a role in bone metabolism and osteoporosis.
While a stronger relationship of 25(OH)D levels with
BMD was found at the femoral neck, SHBG was related
more strongly to the BMD of the femoral trochanter and
the distal radius. The femoral neck predominantly con-
sists of cortical bone, (39) which is more susceptible to
bone loss due to secondary hyperparathyroidism.(5'28)
The femoral trochanter and the distal radius have a
higher content of trabecular bone, which is more sensi-
tive to estrogen deficiency. (4,39,40)
We conclude that 25(OH)D levels below 30 nmol/1 are
associated with secondary hyperparathyroidism, increased
bone turnover, and decreased BMD at the hip. SHBG is
positively related to bone turnover and negatively to tra-
becular bone mass, which may indicate that estrogen activ-
ity influences bone turnover and trabecular bone loss even
in the very old. When vitamin D deficiency is combined with
a high SHBG the secondary hyperparathyroidism is more
severe, while it is almost lacking when SHBG is low. This
suggests that low oestrogen activity causes decreased sensi-
tivity of the gut to 1,25(OH) 2D, leading to higher serum
PTH levels. This increases the impact of vitamin D defi-
ciency. Since vitamin D deficiency according to the 30
nmo1/1 limit is common, it may be an important risk factor
for hip fractures in the elderly in The Netherlands.
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